0746 GMT - Haleon's first-quarter results are consistent with those of peers like Reckitt, as a less severe cold and flu season affected performance, analysts at RBC Capital Markets write in a note. Meanwhile, growth is expected to accelerate over the remainder of the year, and North America had better-than-expected performance amid a declining market, the analysts add. A pain relief miss shows that Advil sales declined with weakness in the U.S., they add. Shares are down 2.4% at 342.30 pence. (aimee.look@wsj.com)

(END) Dow Jones Newswires

April 29, 2026 03:46 ET (07:46 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.